Efficacy and safety of catheter ablation for people with non-paroxysmal atrial fibrillation
- Original Publication: Nyong J, Amit G, Adler AJ, Owolabi OO, Perel P, Prieto-Merino D, Lambiase P, Casas JP, Morillo CA. Efficacy and safety of ablation for people with non-paroxysmal atrial fibrillation. Cochrane Database of Systematic Reviews 2016, Issue 11. Art. No.: CD012088
- This KCE has read for you was prepared by Chris De Laet and Patriek Mistiaen
- Published on 12 December 2017
KEY MESSAGES FROM THE ORIGNAL PUBLICATION
- In people with non-paroxysmal atrial fibrillation evidence suggests the superiority of catheter ablation to antiarrhythmic drugs in achieving freedom from atrial arrhythmias, reducing the need for cardioversion, and reducing cardiac-related hospitalisations, at 12 months.
- This evidence should be interpreted with caution as the number of participants and event rates are low and therefore quality of evidence ranges from moderate to very low.
- There is no conclusive evidence about adverse events such as significant bradycardia (with need for a pacemaker), periprocedural complications and other safety outcomes. There is equally no evidence on other endpoints such as mortality, major adverse cardiac events, quality of life, risk of stroke or risk of embolic events .
- There is no evidence on long-term efficacy (> one year)
KCE has read for you synthesises a recently published high-quality systematic review or health technology assessment with relevance for the Belgian health system.
The original publication was appraised and contextualised by KCE researchers. KCE has read for you is not based on original research conducted by KCE.
More details on methodology can be found on the KCE website.
This document includes
- Key findings of the publication under evaluation
- A contextualisation within the Belgian healthcare system
- Detailed descriptions
Trustworthy original publication
The methodological quality of the systematic review was assessed with the AMSTAR tool.